← Back to Search

Needling Device

Straberi Epistamp Needling Treatment for Postinflammatory Hyperpigmentation (EPH Trial)

N/A
Waitlist Available
Led By Maurice E Wright, MD
Research Sponsored by Universal Skincare Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients willing to consent to 3 months of treatment
Derma Scan showing aging including skin texture, wrinkles, brown spots, and pores.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

EPH Trial Summary

This trialtests a new device to reduce the dark spots caused by acne.

Eligible Conditions
  • Postinflammatory Hyperpigmentation

EPH Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You agree to receive treatment for at least 3 months and are willing to give your permission for it.
Select...
Your skin has signs of aging such as wrinkles, brown spots, and enlarged pores, as seen through a skin scan.
Select...
You are comfortable with being photographed and recorded on video.

EPH Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The Global Aesthetic Improvement Scale (GAIS)
Secondary outcome measures
Overall Skin improvement assessed by Derma Scan
Overall Skin improvement assessed by Post Acne Hyperpigmentation Index (PAHPI)
Photographs
+1 more

EPH Trial Design

2Treatment groups
Experimental Treatment
Group I: Straberi Epistamp Needling TreatmentExperimental Treatment1 Intervention
Non-Randomized treatment for patients with Postinflammatory Hyperpigmentation (PIH) using the Straberi Epistamp needling.
Group II: No TreatmentExperimental Treatment1 Intervention
Non-Randomized patients with Postinflammatory Hyperpigmentation (PIH)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Straberi Epistamp
2022
N/A
~30

Find a Location

Who is running the clinical trial?

Universal Skincare InstituteLead Sponsor
2 Previous Clinical Trials
55 Total Patients Enrolled
Lavish BeautyUNKNOWN
2 Previous Clinical Trials
55 Total Patients Enrolled
Leslie L NesbittStudy ChairUniversal Skincare
2 Previous Clinical Trials
55 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the study accept participants above a certain age threshold?

"This clinical trial is actively seeking patients aged between 21 and 65 years old."

Answered by AI

What is the aggregate amount of individuals participating in this experiment?

"That is correct. According to the information available on clinicaltrials.gov, this medical study was first posted on November 21st 2022 and has been actively recruiting since then. Thirty individuals are needed at one particular location for this trial."

Answered by AI

Who is eligible to become part of this research trial?

"Candidates aged between 21 and 65 that suffer from postinflammatory hyperpigmentation are eligible to take part in this trial. The study is looking for a total of 30 patients."

Answered by AI

Are there vacancies available for this trial to join?

"Correct. Clinicaltrials.gov has evidence that this medical trial, originally posted on November 21st 2022, is recruiting participants at present time. 30 volunteers need to be recruited from one centre."

Answered by AI
~13 spots leftby Apr 2025